2009 Is ImmunoGen’s Make-Or-Break Year
The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.
The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.